Search
Now showing items 1-10 of 58
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity
(2007)
Background: Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk
volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 ...
Filaria dance sign and subclinical hydrocoele in two east African communities with bancroftian filariasis.
(2002)
During population-wide cross-sectional surveys for Wuchereria bancrofti microfilaremia, circulating antigenaemia, and clinical disease in a high and a low endemicity community in East Africa in 1998, a portable ultrasound ...
Establishing and sustaining a healthy vaginal environment:
(2011)
Data from a randomized trial of oral periodic presumptive
treatment (PPT) to reduce vaginal infections were analyzed
to assess the effect of the intervention on a healthy vaginal
environment (normal flora confirmed by ...
Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
(2008-04)
Background: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct
of clinical trials, particularly for trials of preventive technologies such as vaccines that ...
Effective intervention to reduce intravaginal practices among hiv-1 uninfected Kenyan women.
(University of Nairobi, 2014)
Intravaginal practices (IVP) are common among African women and are associated with HIV acquisition. A behavioral intervention to reduce IVP is a potential new HIV risk-reduction strategy. Fifty-eight HIV-1-uninfected ...
Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya Aids vaccine initiative (KAVI), Kenya
(2011)
With the persistent challenges towards controlling the HIV epidemic, there is an ongoing need for research into HIV vaccines and drugs. Sub-Saharan African countries--worst affected by the HIV pandemic--have participated ...
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming
(2006)
Background: Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk
volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 ...
Bancrofyian filariasis infection, disease, and specific antibody response patterns in a high and a low endemicity community in East Africa
(2002)
Bancroftian filariasis infection, disease and specific antibody response patterns in a high and a low endemicity
community in East Africa were analyzed and compared to assess the relationship between these parameters ...
Blunted IL17/IL22 and Pro-Inflammatory Cytokine Responses in the Genital Tract and Blood of HIV-Exposed, Seronegative Female Sex Workers in Kenya
(University of Nairobi, 2012)
Identifying the immune correlates of reduced susceptibility to HIV remains a key goal for the HIV vaccine field, and individuals who are HIV-exposed, seronegative (HESN) may offer important clues. Reduced systemic immune ...
HIV-1 Clade D Is Associated with Increased Rates of CD4 Decline in a Kenyan Cohort
(University of Nairobi, 2012)
HIV-1 is grouped phylogenetically into clades, which may impact rates of HIV-1 disease progression. Clade D infection in particular has been shown to be more pathogenic. Here we confirm in a Nairobi-based prospective female ...